Table 5.

Changes in adjuvant therapy after central pathology

	Non-GIST (N = 19)	PDFGRA exon18 D842V (N = 17)	Wild type (N = 19)
Initially no adjuvant therapy	5	3	4
No. of patients received adjuvant	14	14	15
Unevaluable due to other reasonsa	4	4	8
No. of evaluable patients with adjuvant	10	8	7
Stopped by central pathology	6 (60%)	5 (63%)	0 (0%)
Continued after central pathology	4 (40%)	3 (38%)	7 (100%)

^aImatinib adjuvant therapy was already stopped before returning central pathology due to relapses or patients’ refusal of imatinib due to adverse events